KTTA•benzinga•
Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results
Summary
Pasithea shares rise as early Phase 1 data of PAS-004 shows strong pERK inhibition and tumor shrinkage in advanced cancer patients.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 6, 2025 by benzinga